Avancées technologiques et traitement du diabète

Roy-Fleming, Amélie; Taleb, Nadine

doi:https://doi.org/10.7202/1048943ar

1. [Internet] Mythes et statistiques : Diabète Québec ; 2017 [page consultée le 17 janvier 2018]. Disponible au : http://www.diabete.qc.ca/fr/comprendre-le-diabete/tout-sur-le-diabete/mythes-et-statistiques.

Google Scholar

2. Diabetes C, Complications Trial Research G, Nathan DM, Genuth S, Lachin J, Cleary P, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 ;329(14) :977-86.

Google Scholar

3. Writing Group for the DCCT/EDIC Research Group. Coprogression of Cardiovascular Risk Factors in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care. 2016 ;39(9) :1621-30.

10.2337/dc16-0502 Google Scholar

4. Thabit H, Hovorka R. Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus : a comparative overview and future horizons. Expert Opin Drug Deliv. 2016 ;13(3) :389-400.

10.1517/17425247.2016.1115013 Google Scholar

5. 5.Walsh J, Roberts, R. Pumping Insulin. 5 ed : Torrey Pines Press ; 2012. 332 p.

Google Scholar

6. Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010(1) :CD005103.

Google Scholar

7. Leelarathna L, Roberts SA, Hindle A, Markakis K, Alam T, Chapman A, et al. Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. Diabet Med. 2017 ;34(10) :1372-9.

10.1111/dme.13412 Google Scholar

8. Payk M, Robinson T, Davis D, Atchan M. An integrative review of the psychosocial facilitators and challenges of continuous subcutaneous insulin infusion therapy in type 1 diabetes. J Adv Nurs. 2018 ;74(3) :528-538.

10.1111/jan.13463 Google Scholar

9. [Internet] Programme d’accès au pompes à insuline : Gouvernement du Québec ; 2016 [page consultée le 18 janvier 2018]. Disponible au : http://sante.gouv.qc.ca/programmes-et-mesures-daide/programme-d-acces-aux-pompes-a-insuline/description/.

Google Scholar

10. Reznik Y, Cohen O, Aronson R, Conget I, Runzis S, Castaneda J, et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise) : a randomised open-label controlled trial. Lancet. 2014 ;384(9950) :1265-72.

10.1016/S0140-6736(14)61037-0 Google Scholar

11. Pickup JC, Reznik Y, Sutton AJ. Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes : Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials. Diabetes Care. 2017 ;40(5) :715-22.

10.2337/dc16-2201 Google Scholar

12. Karter AJ, Ackerson LM, Darbinian JA, D’Agostino RB, Jr., Ferrara A, Liu J, et al. Self-monitoring of blood glucose levels and glycemic control : the Northern California Kaiser Permanente Diabetes registry. Am J Med. 2001 ;111(1) :1-9.

10.1016/S0002-9343(01)00742-2 Google Scholar

13. Miller KM, Beck RW, Bergenstal RM, Goland RS, Haller MJ, McGill JB, et al. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care. 2013 ;36(7) :2009-14.

10.2337/dc12-1770 Google Scholar

14. Klonoff DC. Continuous glucose monitoring : roadmap for 21st century diabetes therapy. Diabetes Care. 2005 ;28(5) :1231-9.

10.2337/diacare.28.5.1231 Google Scholar

15. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Sensor-augmented pump therapy for A1C reduction (STAR 3) study : results from the 6-month continuation phase. Diabetes Care. 2011 ;34(11) :2403-5.

10.2337/dc11-1248 Google Scholar

16. Taleb N, Emami A, Suppere C, Messier V, Legault L, Chiasson JL, et al. Comparison of Two Continuous Glucose Monitoring Systems, Dexcom G4 Platinum and Medtronic Paradigm Veo Enlite System, at Rest and During Exercise. Diabetes Technol Ther. 2016 ;18(9) :561-7

10.1089/dia.2015.0394 Google Scholar

17. Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System. Diabetes Technol Ther. 2015 ;17(11) :787-94.

10.1089/dia.2014.0378 Google Scholar

18. Leelarathna L, Wilmot G. Flash forward : a review of flash glucose monitoring. Diabet Med. 2018 ;35(4) :472-482

10.1111/dme.13584 Google Scholar

19. [Internet] Abbott. The NEXT FRONTIER in the management of diabetes AMBULATORY GLUCOSE PROFILE (AGP) 2016 [page consultée le 24 janvier 2018]. Disponible au : https://diabetesfrontier.com/actionable-insights/#sthash.JXHaf51E.dpbs.

Google Scholar

20. Ehrhardt NM, Chellappa M, Walker MS, Fonda SJ, Vigersky RA. The effect of real-time continuous glucose monitoring on glycemic control in patients with type 2 diabetes mellitus. J Diabetes Sci Technol. 2011 ;5(3) :668-75.

10.1177/193229681100500320 Google Scholar

21. Garg SK, Voelmle MK, Gottlieb P. Feasibility of 10-day use of a continuous glucose-monitoring system in adults with type 1 diabetes. Diabetes Care. 2009 ;32(3) :436-8.

10.2337/dc08-1745 Google Scholar

22. Rodbard D. Continuous Glucose Monitoring : A Review of Successes, Challenges, and Opportunities. Diabetes Technol Ther. 2016 ;18 Suppl 2 :S23-213.

10.1089/dia.2015.0417 Google Scholar

23. Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections : The DIAMOND Randomized Clinical Trial. JAMA. 2017 ;317(4) :371-8.

10.1001/jama.2016.19975 Google Scholar

24. Soupal J, Petruzelkova L, Flekac M, Pelcl T, Matoulek M, Dankova M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up : A COMISAIR Study. Diabetes Technol Ther. 2016 ;18(9) :532-8.

10.1089/dia.2016.0171 Google Scholar

25. Gandhi GY, Kovalaske M, Kudva Y, Walsh K, Elamin MB, Beers M, et al. Efficacy of continuous glucose monitoring in improving glycemic control and reducing hypoglycemia : a systematic review and meta-analysis of randomized trials. J Diabetes Sci Technol. 2011 ;5(4) :952-65.

10.1177/193229681100500419 Google Scholar

26. Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, Krger J, Weitgasser R, Bolinder J. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy : a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia. 2018 ;61(3) :539-550.

10.1007/s00125-017-4527-5 Google Scholar

27. Reddy M, Jugnee N, El Laboudi A, Spanudakis E, Anantharaja S, Oliver N. A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia. Diabet Med. 2018 ;35(4) :483-490.

10.1111/dme.13561 Google Scholar

28. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes. Diabetes Ther. 2017 ;8(3) :573-86.

10.1007/s13300-017-0255-6 Google Scholar

29. Wong JC, Foster NC, Maahs DM, Raghinaru D, Bergenstal RM, Ahmann AJ, et al. Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. Diabetes Care. 2014 ;37(10) :2702-9.

10.2337/dc14-0303 Google Scholar

30. Thabit H, Hovorka R. Coming of age : the artificial pancreas for type 1 diabetes. Diabetologia. 2016 ;59(9) :1795-805.

10.1007/s00125-016-4022-4 Google Scholar

31. Taleb N, Haidar A, Messier V, Gingras V, Legault L, Rabasa-Lhoret R. Glucagon in artificial pancreas systems : Potential benefits and safety profile of future chronic use. Diabetes Obes Metab. 2017 ;19(1) :13-23.

10.1111/dom.12789 Google Scholar

32. Rabasa-Lhoret et Nadine Taleb. Pancréas artificiel externe et diabète de type 1 une solution thérapeutique bientôt disponible. Diabète et Obésité. 2017 ;12(10) :177-83.

Google Scholar

33. Voelker R. « Artificial Pancreas » Is Approved. JAMA. 2016 ;316(19) :1957.

Google Scholar

34. Kropff J, Del Favero S, Place J, Toffanin C, Visentin R, Monaro M, et al. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions : a randomised crossover trial. Lancet Diabetes Endocrinol. 2015 ;3(12) :939-47.

10.1016/S2213-8587(15)00335-6 Google Scholar

35. Thabit H, Tauschmann M, Allen JM, Leelarathna L, Hartnell S, Wilinska ME, et al. Home Use of an Artificial Beta Cell in Type 1 Diabetes. N Engl J Med. 2015 ;373(22) :2129-40.

10.1056/NEJMoa1509351 Google Scholar

36. Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes : a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017 ;5(7) :501-12.

10.1016/S2213-8587(17)30167-5 Google Scholar

37. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin : Pharmacology, Physiology, and Clinical Potential. Pharmacol Rev. 2015 ;67(3) :564-600.

10.1124/pr.115.010629 Google Scholar

38. Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006 ;29(10) :2189-95.

10.2337/dc06-0042 Google Scholar

39. Fortin A, Rabasa-Lhoret R, Roy-Fleming A, Desjardins K, Brazeau AS, Ladouceur M, et al. Practices, perceptions and expectations for carbohydrate counting in patients with type 1 diabetes - Results from an online survey. Diabetes Res Clin Pract. 2017 ;126 :214-21.

10.1016/j.diabres.2017.02.022 Google Scholar

40. Ziegler R, Freckmann G, Heinemann L. Boluses in Insulin Therapy. J Diabetes Sci Technol. 2017 ;11(1) :165-71.

10.1177/1932296816653142 Google Scholar

41. Heinemann L. Insulin pump therapy : what is the evidence for using different types of boluses for coverage of prandial insulin requirements? J Diabetes Sci Technol. 2009 ;3(6) :1490-500.

10.1177/193229680900300631 Google Scholar

42. Gingras V, Taleb N, Roy-Fleming A, Legault L, Rabasa-Lhoret R. The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes. Diabetes Obes Metab. 2018 ;20(2) :245-56.

10.1111/dom.13052 Google Scholar

43. Gingras V, Rabasa-Lhoret R, Messier V, Ladouceur M, Legault L, Haidar A. Efficacy of dual-hormone artificial pancreas to alleviate the carbohydrate-counting burden of type 1 diabetes : A randomized crossover trial. Diabetes Metab. 2016 ;42(1) :47-54.

10.1016/j.diabet.2015.05.001 Google Scholar

44. Gingras V, Haidar A, Messier V, Legault L, Ladouceur M, Rabasa-Lhoret R. A Simplified Semiquantitative Meal Bolus Strategy Combined with Single- and Dual-Hormone Closed-Loop Delivery in Patients with Type 1 Diabetes : A Pilot Study. Diabetes Technol Ther. 2016 ;18(8) :464-71.

10.1089/dia.2016.0043 Google Scholar

45. [Internet] Omnipod. Ressources à l’intention des patients utilisateurs d’Omnipod [consulté le 18 janvier 2018]. Disponible au : https://www.myomnipod.ca/content/fr/centre-d-apprentissage/.

Google Scholar

46. [Internet] Medtronic. La pompe : une solution possible [consulté le 18 janvier 2018]. Disponible au : https://www.medtronicdiabete.ca/attenuation-complications/pompe-insuline-solution-possible.

Google Scholar

Avancées technologiques et traitement du diabète[Record]

Bibliographie

Appendices

Bibliographie

Citation Tools

Cite this article

Export the record for this article